NEWTON, Mass. & BERLIN--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) and Epigenomics AG (FSE:ECX) today announced an agreement to offer Epigenomics’ proprietary DNA methylation services through Clinical Data’s service division, Cogenics. Under this agreement, Cogenics will promote to its customers Epigenomics’ comprehensive portfolio of DNA methylation services including genome-wide DNA methylation analysis, bisulfite sequencing, and real-time PCR technologies, which are performed in Epigenomics’ laboratories in Germany. Additionally, the companies plan to offer regulated (GLP) DNA methylation analyses in Cogenics’ laboratories in the US. Under the agreement, Epigenomics will promote Cogenics’ comprehensive pharmacogenomics and molecular biology services to its DNA methylation biomarker development partners and customers that Epigenomics serves through its Clinical Solutions group.
